Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Cancer Tumor Organoids Modeling, Technology & Personalized Cancer Research Insight 2025 - ResearchAndMarkets.com

January 20, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 20, 2020--

The “Global Cancer Tumor Organoids Modeling, Technology & Personalized Cancer Research Insight 2025” report has been added to ResearchAndMarkets.com’s offering.

The development of cancer organoids has transformed the widespread adoption of the traditional 2D cell lines in the research community. The technology of cancer organoids holds significant potential to study a variety of areas such as cancer disease pathology, cancer biology, precision medicine, drug development, drug testing and drug efficacy testing. For the mentioned areas, cancer organoid technology constitutes tremendous informative complimentary approaches to the already available two-dimensional culture method and animal model system.

On an average, the development of organoid culture represents a novel technology for studying human disease and human development. The ability of the organoids to resemble the original human tissue, form the correct type of cell and to perform the specific functions of the tissues helps in gaining the confidence of working on human cancer organoids and for the development of treatments against human cancers.

Cancer organoids faithfully recapitulate the different aspects of tissue composition, function and architecture ex vivo and by doing so they set a great example of an advanced technology that comes with the possibility of opening up and identifying novel therapeutics strategies in personalizing the human disease model.

All this advancement should enable cancer organoid technology to develop its place at the top and marking itself as an important tool in predicting the response of cancer patients towards cancer treatment in the future. Up to now, the majority of cancer organoids have been generated for adenocarcinomas and less organoids are currently available for the squamous cell carcinomas.

The technology of developing a complete organ in vitro from small amount of cells is considered as groundbreaking as the discovery of antibiotics, vaccines and chemotherapy in the fight against different human diseases. The technology requires few years and some advancement, to be dominant over the other available technologies.

Report Highlights:

Key Topics Covered:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/gwqbor

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200120005137/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/20/2020 05:03 AM/DISC: 01/20/2020 05:03 AM